Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768506 | 0.83 | DRD3 (0.50) | ESR2DRD3KCNH2DRD2 | |
| SCHEMBL4565400 | 0.81 | GPR119 (0.59) | ESR2NR1H2DRD3PKMNPC1 | |
| SCHEMBL4765610 | 0.79 | ESR2 (0.49) | ESR2NR1H2DRD3KCNH2DRD2 | |
| SCHEMBL5453239 | 0.78 | ESR2 (0.55) | ESR2NR1H2NPC1RAB9AUSP30 | |
| SCHEMBL4763630 | 0.78 | ESR2 (0.50) | ESR2NR1H2NPC1RAB9AGPR119 | |
| SCHEMBL25574615 | 0.78 | ESR2 (0.58) | ESR2NR1H2USP30GPR119HDAC4 | |
| SCHEMBL5467960 | 0.77 | ESR2 (0.68) | ESR2NR1H2NPC1RAB9AGPR119 | |
| SCHEMBL7868104 | 0.77 | ESR2 (0.63) | ESR2NR1H2NPC1RAB9AGPR119 | |
| SCHEMBL5661929 | 0.76 | GPR119 (0.54) | ESR2NR1H2PKMNPC1RAB9A | |
| SCHEMBL1263942 | 0.76 | ESR2 (0.61) | ESR2NR1H2NPC1RAB9AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725241-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1335915-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2008-01-02 | — | — | EP | disclosed |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725241-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-1119563-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005094835-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1335915-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| US-6605607-B1 | Antihypertensives; hyperprolactinaemia related conditions; certain central nervous system disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-12 | — | — | US | disclosed |
| WO-2002040471-A9 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002040471-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | ESR2 698/4885NR1H2 204/4885DRD3 1/4885 |
| US-20070185088-A1 | M3 muscarinic acetylchoine receptor antagonists | CHRM3, CHRM2, CHRM5 | ESR2 1164/4885NR1H2 233/4885DRD3 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.